<DOC>
	<DOCNO>NCT00069186</DOCNO>
	<brief_summary>The purpose study determine whether nine month administration creatine monohydrate result increase muscle strength patient amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Study Creatine Monohydrate Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Introduction : Twenty-one ALS patient enrol placebo control pilot study Carolinas Neuromuscular/ALS-MDA Center , The University Texas Health Science Center San Antonio The University New Mexico Albuquerque . At time point sample nine month period , patient take creatine monohydrate either significantly great improvement strength modest decline compare patient take placebo . Overall analysis variance significant effect drug ( p=0.002 ) time ( p &lt; 0.001 ) .The pilot study also show quality life , measure ALSFRS-R , correlate significantly observe change muscle strength ( MVIC ) . Phase III Study : The primary objective study determine whether treatment creatine monohydrate result increase muscle strength relative placebo patient amyotrophic lateral sclerosis ( ALS ) , three month , end nine-month treatment period . The study Phase III , eight-center , double-blind , placebo-controlled , randomized clinical trial design evaluate safety efficacy creatine monohydrate patient fulfil eligibility criterion . The subject ( n=156 ) randomize 1:1 ratio receive treatment highly purified creatine monohydrate placebo ( Dextrose , USP ) nine month . The subject administer 10 gram creatine monohydrate per day first five day , 5 gram per day thereafter . Each subject follow nine-month treatment period . The primary outcome measure study change upper extremity motor function three week , end nine-month treatment period test MVIC . Strength ten arm muscle measure ( bilateral shoulder elbow flexion/extension grip ) . Patient safety assure ongoing review report adverse event , clinical laboratory data , measurement vital sign . These test include : measurement MVIC muscle fatigue , measurement FVC , completion ALSFRS-R SF-12 quality life instrument , review potential adverse effect , determination vital sign weight , serum creatinine BUN , urine dipstick protein .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>A clinical diagnosis probable definite labsupported ALS , either SALS FALS , accord modify El Escorial criterion . Males female , 21 80 year age . Patients receive treatment RilutekÂ® ( riluzole ) must stable dose least 30 day immediately prior enrollment . Women childbearing potential must nonlactating surgically sterile use effective method birth control ( double barrier oral contraception ) negative pregnancy test . Women consider menopausal menstrual cycle ( period ) two year . Disease duration less five year since symptom onset . At least 5 10 testable upper extremity muscle group MRC grade 4 well . The patient must give informed consent approve appropriate Institutional Review Board ( IRB ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Creatine</keyword>
	<keyword>Creatine Monohydrate</keyword>
	<keyword>Muscle Strength</keyword>
</DOC>